Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 ...